Protara Therapeutics: End Of 2025 Proving Eventful Indeed (NASDAQ:TARA)

Core Insights - The article maintains optimism for Protara Therapeutics (TARA) regarding their bladder cancer pipeline, particularly in addressing drug shortages in the non-metastatic setting and exploring a novel indication [1] Company Overview - Protara Therapeutics is focused on developing treatments for bladder cancer, with a specific emphasis on addressing drug shortages [1] Analyst Background - The author has a PhD in biochemistry and extensive experience analyzing clinical trials and biotech companies, indicating a strong foundation for evaluating the company's prospects [1]